HC Wainwright Reaffirms "Buy" Rating for Compass Therapeutics (NASDAQ:CMPX)

HC Wainwright restated their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX - Free Report) in a report released on Monday,Benzinga reports. The firm currently has a $10.00 price objective on the stock.

Other equities analysts have also recently issued research reports about the company. LADENBURG THALM/SH SH upgraded Compass Therapeutics from a "neutral" rating to a "buy" rating and set a $5.00 price objective for the company in a report on Monday, September 16th. Wedbush reiterated an "outperform" rating and issued a $8.00 target price on shares of Compass Therapeutics in a report on Wednesday, August 7th.

Compass Therapeutics Trading Up 5.6 %

CMPX traded up $0.10 during trading on Monday, reaching $1.90. The stock had a trading volume of 412,686 shares, compared to its average volume of 432,720. Compass Therapeutics has a one year low of $0.77 and a one year high of $2.34. The stock's 50 day moving average is $1.74 and its two-hundred day moving average is $1.41. The company has a market capitalization of $261.42 million, a price-to-earnings ratio of -5.07 and a beta of 0.92.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.10). The firm had revenue of $0.85 million during the quarter. On average, equities research analysts predict that Compass Therapeutics will post -0.42 earnings per share for the current year.

Institutional Investors Weigh In On Compass Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CMPX. Rovin Capital UT ADV acquired a new stake in Compass Therapeutics in the third quarter valued at approximately $25,000. Intech Investment Management LLC acquired a new position in Compass Therapeutics during the 3rd quarter worth $30,000. Cubist Systematic Strategies LLC acquired a new position in Compass Therapeutics during the 2nd quarter worth $41,000. Panagora Asset Management Inc. acquired a new position in shares of Compass Therapeutics during the 2nd quarter worth about $68,000. Finally, SG Americas Securities LLC boosted its position in shares of Compass Therapeutics by 16.6% during the 3rd quarter. SG Americas Securities LLC now owns 38,665 shares of the company's stock worth $71,000 after acquiring an additional 5,515 shares in the last quarter. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.